Literature DB >> 9437558

Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem.

L Bahamondes1, N M Marchi, H M Nakagava, M L de Melo, M de L Cristofoletti, E Pellini, R H Scozzafave, C Petta.   

Abstract

The objective of this study was to evaluate women's acceptance of and ability to self-administrate the injectable contraceptive Cyclofem using prefilled UniJect devices. A total of 102 women were invited to participate in the study. Fourteen women (13.7%) refused to participate. Of the remaining 88 women, 32 women (31.4%) consented to participate and were trained using oranges but were still afraid of the procedure and ultimately refused to self-administer the injections. Only 56 women (55%) ultimately self-injected Cyclofem with UniJect. They performed a total of 144 injections, all of them on the ventral side of the thigh. When nurses evaluated women's ability to activate the devices, they found that more than 80% were successful in both the group of women that later self-administered the injections and the group that did not. The evaluation of the self-administered injection technique showed that more than 90% of the women correctly self-administered the contraceptive using UniJect. With respect to the opinion of the women about the self-administration of the contraceptive, more than 50% (32 of 56) of women who self-injected preferred to self-administer the injection and said that they wished to continue with the self-administration, one-third (17) reported that they were afraid, and seven women (12.5%) expressed the opinion that the injection in the thigh was more painful than the administration in the buttocks or arm. In conclusion, our study showed that women can be trained to successfully self-administer the monthly injectable contraceptive Cyclofem and generally respond positively to UniJect.

Entities:  

Keywords:  Acceptors--women; Americas; Brazil; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Contraceptive Usage; Developing Countries; Equipment And Supplies; Family Planning; Family Planning Programs; Injectables; Latin America; Medroxyprogesterone Acetate; Method Acceptability; Research Methodology; Research Report; South America; Syringe

Mesh:

Substances:

Year:  1997        PMID: 9437558     DOI: 10.1016/s0010-7824(97)00162-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  Barriers to contraceptive use in product labeling and practice guidelines.

Authors:  Daniel Grossman; Charlotte Ellertson; Katrina Abuabara; Kelly Blanchard; Francisco T Rivas
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

2.  Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.

Authors:  Anitra Beasley; Katharine O'Connell White; Serge Cremers; Carolyn Westhoff
Journal:  Contraception       Date:  2014-02-07       Impact factor: 3.375

3.  Equity in access to long-acting injectables in the USA.

Authors:  J Carlo Hojilla; Monica Gandhi; Derek D Satre; Mallory O Johnson; Parya Saberi
Journal:  Lancet HIV       Date:  2022-02-04       Impact factor: 12.767

Review 4.  Combination injectable contraceptives for contraception.

Authors:  Maria F Gallo; David A Grimes; Laureen M Lopez; Kenneth F Schulz; Catherine d'Arcangues
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

5.  A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection.

Authors:  Jane Cover; Allen Namagembe; Justine Tumusiime; Jeanette Lim; Jennifer Kidwell Drake; Anthony K Mbonye
Journal:  Contraception       Date:  2016-10-24       Impact factor: 3.375

Review 6.  Self-administration of injectable contraceptives: a systematic review.

Authors:  C R Kim; M S Fønhus; B Ganatra
Journal:  BJOG       Date:  2016-08-23       Impact factor: 6.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.